Advertisement
Screener

ALDEYRA THERAPEUTICS, INC. (ALDX) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

ALDEYRA THERAPEUTICS, INC. Research and Development Expense

ALDEYRA THERAPEUTICS, INC. (ALDX) reported Research and Development Expense of $3.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06

  • ALDEYRA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $3.48M, a 59.03% decline year-over-year.
  • ALDEYRA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $2.41M, a 67.54% decline year-over-year.
  • ALDEYRA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $4.30M, a 70.58% decline year-over-year.
  • ALDEYRA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $5.43M, a 56.35% decline year-over-year.
  • ALDEYRA THERAPEUTICS, INC. research and development expense for fiscal 2025 was $25.66M, a 46.78% decline from fiscal 2024.
  • ALDEYRA THERAPEUTICS, INC. research and development expense for fiscal 2024 was $48.22M, a 63.70% increase from fiscal 2023.
  • ALDEYRA THERAPEUTICS, INC. research and development expense for fiscal 2023 was $29.46M, a 37.73% decline from fiscal 2022.
  • ALDEYRA THERAPEUTICS, INC. research and development expense for fiscal 2022 was $47.31M, a 5.27% increase from fiscal 2021.
Period endResearch and Development Expense 3 monthResearch and Development Expense 6 monthResearch and Development Expense 9 monthResearch and Development Expense 12 monthResearch and Development Expense 116 month
2026-06-30$3.48M
10-Q · filed 2026-08-06
$5.89M
10-Q · filed 2026-08-06
$10.20M
derived: sum of 3 quarters · filed 2026-08-06
$15.63M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$2.41M
10-Q · filed 2026-05-07
$6.71M
derived: sum of 2 quarters · filed 2026-05-07
$12.14M
derived: sum of 3 quarters · filed 2026-05-07
$20.65M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$4.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
$9.73M
derived: sum of 2 quarters · filed 2026-02-27
$18.24M
derived: sum of 3 quarters · filed 2026-08-06
$25.66M
10-K · filed 2026-02-27
2025-09-30$5.43M
10-Q · filed 2025-11-05
$13.94M
derived: sum of 2 quarters · filed 2026-08-06
$21.36M
10-Q · filed 2025-11-05
$35.99M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$8.51M
10-Q · filed 2026-08-06
$15.93M
10-Q · filed 2026-08-06
$30.56M
derived: sum of 3 quarters · filed 2026-08-06
$43.00M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$7.42M
10-Q · filed 2026-05-07
$22.05M
derived: sum of 2 quarters · filed 2026-05-07
$34.49M
derived: sum of 3 quarters · filed 2026-05-07
$49.46M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$14.63M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
$27.07M
derived: sum of 2 quarters · filed 2026-02-27
$42.04M
derived: sum of 3 quarters · filed 2026-02-27
$48.22M
10-K · filed 2026-02-27
2024-09-30$12.44M
10-Q · filed 2025-11-05
$27.41M
derived: sum of 2 quarters · filed 2025-11-05
$33.59M
10-Q · filed 2025-11-05
$37.89M
derived: sum of 4 quarters · filed 2025-11-05
2024-06-30$14.97M
10-Q · filed 2025-08-07
$21.15M
10-Q · filed 2025-08-07
$25.45M
derived: sum of 3 quarters · filed 2025-08-07
$32.41M
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31$6.18M
10-Q · filed 2025-05-14
$10.48M
derived: sum of 2 quarters · filed 2025-05-14
$17.44M
derived: sum of 3 quarters · filed 2025-05-14
$24.41M
derived: sum of 4 quarters · filed 2025-05-14
2023-12-31$4.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28
$11.26M
derived: sum of 2 quarters · filed 2025-02-28
$18.22M
derived: sum of 3 quarters · filed 2025-02-28
$29.46M
10-K · filed 2025-02-28
2023-09-30$6.96M
10-Q · filed 2024-11-07
$13.92M
derived: sum of 2 quarters · filed 2024-11-07
$25.16M
10-Q · filed 2024-11-07
$34.12M
derived: sum of 4 quarters · filed 2024-11-07
2023-06-30$6.96M
10-Q · filed 2024-08-01
$18.20M
10-Q · filed 2024-08-01
$27.16M
derived: sum of 3 quarters · filed 2024-08-01
$38.70M
derived: sum of 4 quarters · filed 2024-08-01
2023-03-31$11.24M
10-Q · filed 2024-05-02
$20.20M
derived: sum of 2 quarters · filed 2024-05-02
$31.74M
derived: sum of 3 quarters · filed 2024-05-02
$46.31M
derived: sum of 4 quarters · filed 2024-05-02
2022-12-31$8.96M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07
$20.50M
derived: sum of 2 quarters · filed 2024-03-07
$35.07M
derived: sum of 3 quarters · filed 2024-03-07
$47.31M
10-K · filed 2024-03-07
2022-09-30$11.54M
10-Q · filed 2023-11-03
$26.11M
derived: sum of 2 quarters · filed 2023-11-03
$38.34M
10-Q · filed 2023-11-03
$51.19M
derived: sum of 4 quarters · filed 2023-11-03
2022-06-30$14.57M
10-Q · filed 2023-08-03
$26.80M
10-Q · filed 2023-08-03
$39.65M
derived: sum of 3 quarters · filed 2023-08-03
$52.54M
derived: sum of 4 quarters · filed 2023-08-03
2022-03-31$12.23M
10-Q · filed 2023-05-04
$25.08M
derived: sum of 2 quarters · filed 2023-05-04
$37.97M
derived: sum of 3 quarters · filed 2023-05-04
$49.44M
derived: sum of 4 quarters · filed 2023-05-04
2021-12-31$12.84M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09
$25.74M
derived: sum of 2 quarters · filed 2023-03-09
$37.21M
derived: sum of 3 quarters · filed 2023-03-09
$44.94M
10-K · filed 2023-03-09
2021-09-30$12.89M
10-Q · filed 2022-11-10
$24.37M
derived: sum of 2 quarters · filed 2022-11-10
$32.10M
10-Q · filed 2022-11-10
$39.12M
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30$11.47M
10-Q · filed 2022-08-05
$19.20M
10-Q · filed 2022-08-05
$26.23M
derived: sum of 3 quarters · filed 2022-08-05
$32.36M
derived: sum of 4 quarters · filed 2022-08-05
2021-03-31$7.73M
10-Q · filed 2022-05-05
$14.75M
derived: sum of 2 quarters · filed 2022-05-05
$20.89M
derived: sum of 3 quarters · filed 2022-05-05
$25.77M
derived: sum of 4 quarters · filed 2022-05-05
2020-12-31$7.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17
$13.16M
derived: sum of 2 quarters · filed 2022-03-17
$18.05M
derived: sum of 3 quarters · filed 2022-03-17
$24.68M
10-K · filed 2022-03-17
2020-09-30$6.13M
10-Q · filed 2021-10-28
$11.02M
derived: sum of 2 quarters · filed 2021-10-28
$17.65M
10-Q · filed 2021-10-28
$27.27M
derived: sum of 4 quarters · filed 2021-10-28
2020-06-30$4.89M
10-Q · filed 2021-08-05
$11.52M
10-Q · filed 2021-08-05
$21.13M
derived: sum of 3 quarters · filed 2021-08-05
$37.36M
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31$6.63M
10-Q · filed 2021-05-06
$16.25M
derived: sum of 2 quarters · filed 2021-05-06
$32.47M
derived: sum of 3 quarters · filed 2021-05-06
$43.14M
derived: sum of 4 quarters · filed 2021-05-06
2019-12-31$9.61M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11
$25.84M
derived: sum of 2 quarters · filed 2021-03-11
$36.50M
derived: sum of 3 quarters · filed 2021-03-11
$44.35M
10-K · filed 2021-03-11
2019-09-30$16.22M
10-Q · filed 2020-11-05
$26.89M
derived: sum of 2 quarters · filed 2020-11-05
$34.74M
10-Q · filed 2020-11-05
$43.29M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30$10.66M
10-Q · filed 2020-08-06
$18.51M
10-Q · filed 2020-08-06
$27.06M
derived: sum of 3 quarters · filed 2020-08-06
$34.94M
derived: sum of 4 quarters · filed 2020-08-06
2019-03-31$7.85M
10-Q · filed 2020-05-07
$16.40M
derived: sum of 2 quarters · filed 2020-05-07
$24.28M
derived: sum of 3 quarters · filed 2020-05-07
$31.07M
derived: sum of 4 quarters · filed 2020-05-07
2018-12-31$8.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
$16.43M
derived: sum of 2 quarters · filed 2020-03-12
$23.22M
derived: sum of 3 quarters · filed 2020-03-12
$29.82M
10-K · filed 2020-03-12
2018-09-30$7.88M
10-Q · filed 2019-11-07
$14.67M
derived: sum of 2 quarters · filed 2019-11-07
$21.27M
10-Q · filed 2019-11-07
$26.82M
derived: sum of 4 quarters · filed 2019-11-07
2018-06-30$6.79M
10-Q · filed 2019-08-09
$13.39M
10-Q · filed 2019-08-09
$18.94M
derived: sum of 3 quarters · filed 2019-08-09
$22.48M
derived: sum of 4 quarters · filed 2019-08-09
2018-03-31$6.60M
10-Q · filed 2019-05-10
$12.15M
derived: sum of 2 quarters · filed 2019-05-10
$15.68M
derived: sum of 3 quarters · filed 2019-05-10
$19.53M
derived: sum of 4 quarters · filed 2019-05-10
2017-12-31$5.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08
$9.08M
derived: sum of 2 quarters · filed 2019-03-08
$12.93M
derived: sum of 3 quarters · filed 2019-03-08
$16.30M
10-K · filed 2019-03-08
2017-09-30$3.54M
10-Q · filed 2018-11-14
$7.39M
derived: sum of 2 quarters · filed 2018-11-14
$10.76M
10-Q · filed 2018-11-14
$14.20M
derived: sum of 4 quarters · filed 2018-11-14
2017-06-30$3.85M
10-Q · filed 2018-08-09
$7.22M
10-Q · filed 2018-08-09
$10.67M
derived: sum of 3 quarters · filed 2018-08-09
$14.04M
derived: sum of 4 quarters · filed 2018-08-09
2017-03-31$3.37M
10-Q · filed 2018-05-15
$6.82M
derived: sum of 2 quarters · filed 2018-03-29
$10.20M
derived: sum of 3 quarters · filed 2018-03-29
$13.03M
derived: sum of 4 quarters · filed 2018-03-29
2016-12-31$3.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29
$6.83M
derived: sum of 2 quarters · filed 2018-03-29
$9.66M
derived: sum of 3 quarters · filed 2018-03-29
$13.18M
10-K · filed 2018-03-29
2016-09-30$3.38M
10-Q · filed 2017-11-09
$6.21M
derived: sum of 2 quarters · filed 2017-11-09
$9.73M
10-Q · filed 2017-11-09
$12.84M
derived: sum of 4 quarters · filed 2017-11-09
2016-06-30$2.83M
10-Q · filed 2017-08-07
$6.35M
10-Q · filed 2017-08-07
$9.46M
derived: sum of 3 quarters · filed 2017-08-07
$11.53M
derived: sum of 4 quarters · filed 2017-08-07
2016-03-31$3.51M
10-Q · filed 2017-05-15
$6.62M
derived: sum of 2 quarters · filed 2017-05-15
$8.70M
derived: sum of 3 quarters · filed 2017-05-15
$9.95M
derived: sum of 4 quarters · filed 2017-05-15
2015-12-31$3.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30
$5.19M
derived: sum of 2 quarters · filed 2017-03-30
$6.44M
derived: sum of 3 quarters · filed 2017-03-30
$7.57M
10-K · filed 2017-03-30
2015-09-30$2.08M
10-Q · filed 2016-11-14
$3.33M
derived: sum of 2 quarters · filed 2016-11-14
$4.46M
10-Q · filed 2016-11-14
$5.87M
derived: sum of 4 quarters · filed 2016-11-14
2015-06-30$1.25M
10-Q · filed 2016-08-10
$2.39M
10-Q · filed 2016-08-10
$3.79M
derived: sum of 3 quarters · filed 2016-08-10
$4.98M
derived: sum of 4 quarters · filed 2016-08-10
2015-03-31$1.14M
10-Q · filed 2016-05-09
$2.54M
derived: sum of 2 quarters · filed 2016-05-09
$3.74M
derived: sum of 3 quarters · filed 2016-05-09
$4.40M
derived: sum of 4 quarters · filed 2016-05-09
2014-12-31$1.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30
$2.60M
derived: sum of 2 quarters · filed 2016-03-30
$3.26M
derived: sum of 3 quarters · filed 2016-03-30
$3.71M
10-K · filed 2016-03-30
2014-09-30$1.20M
10-Q · filed 2015-11-13
$1.86M
derived: sum of 2 quarters · filed 2015-11-13
$2.30M
10-Q · filed 2015-11-13
$2.70M
derived: sum of 4 quarters · filed 2015-11-13
2014-06-30$663.91K
10-Q · filed 2015-08-14
$1.11M
10-Q · filed 2015-08-14
$1.51M
derived: sum of 3 quarters · filed 2015-08-14
$2.17M
derived: sum of 4 quarters · filed 2015-08-14
2014-03-31$444.28K
10-Q · filed 2015-05-14
$844.64K
derived: sum of 2 quarters · filed 2015-05-14
$1.51M
derived: sum of 3 quarters · filed 2015-05-14
$1.84M
derived: sum of 4 quarters · filed 2015-05-14
$13.29M
10-Q · filed 2014-06-11
2013-12-31$400.36K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-23
$1.07M
derived: sum of 2 quarters · filed 2015-03-23
$1.39M
derived: sum of 3 quarters · filed 2015-03-23
$1.54M
10-K · filed 2015-03-23
2013-09-30$666.04K
10-Q · filed 2014-11-12
$991.09K
derived: sum of 2 quarters · filed 2014-11-12
$1.14M
10-Q · filed 2014-11-12
2013-06-30$325.05K
10-Q · filed 2014-08-07
$475.28K
10-Q · filed 2014-08-07
2013-03-31$150.23K
10-Q · filed 2014-06-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cingulate Inc. (CING)United States$0.073B-2.64
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41
Lunai Bioworks Inc. (LNAI)United States$0.072B-0.11
OS Therapies Inc (OSTX)United States$0.076B-2.17
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
TENAX THERAPEUTICS, INC. (TENX)United States$0.071B-7.17
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
iBio, Inc. (IBIO)United States$0.077B-2.94
MAIA Biotechnology, Inc. (MAIA)United States$0.077B-2.30